Prostatic Urethra Implant Delivery System for Minimally Invasive BPH Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional surgical methods for treating benign prostatic hyperplasia (BPH) are invasive, irreversible, and associated with significant drawbacks such as risk of infection, sexual dysfunction, and recurrence of urinary symptoms, necessitating the development of less invasive and reversible treatments.
Innovation Solution
A system for delivering and deploying an implant within the prostatic urethra using an elongated sheath and pusher mechanism, allowing for controlled deployment and repositioning of the implant to expand the urethra without tissue removal, compatible with standard cystoscopes and urological techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional surgical procedures are used to remove prostatic tissue, then urinary outflow obstruction is relieved, but the treatment becomes irreversible and carries risks of infection, sexual dysfunction, and incontinence
Solution Approach 1:
The implant is extracted from the delivery system through a controlled deployment mechanism where the pusher advances to push the implant out of the sheath, allowing the implant to be deployed into the prostatic urethra without removing any prostatic tissue
Solution Approach 2:
The implant acts as an intermediary device that is inserted into the prostatic urethra to mechanically push against the enlarged prostate lobes, thereby relieving urinary outflow obstruction without requiring surgical removal of tissue or use of energy-based ablation methods
2Productivity
If traditional surgical approaches are used, then prostatic tissue is removed to relieve obstruction, but the procedure requires hospitalization, anesthesia, and has significant recovery time
Solution Approach 1:
The mechanical surgical resection system is replaced with a minimally invasive implant delivery system that uses a cystoscope and delivery catheter to insert an expandable implant, eliminating the need for surgical incisions, anesthesia, and hospitalization while achieving similar therapeutic effects
Solution Approach 2:
The treatment approach changes from tissue removal (surgical resection) to mechanical compression (implant deployment), fundamentally altering the therapeutic parameter from subtractive to additive/mechanical, thereby reducing invasiveness and recovery time
3Ease of operation
If prostatic tissue is removed surgically, then urinary flow is improved, but sexual function and continence may be permanently affected
Solution Approach 1:
The treatment effect is segmented into two components: the implant provides mechanical compression to relieve obstruction and improve urinary flow, while the surrounding prostatic tissue and sphincter mechanisms remain intact to preserve sexual function and continence
Solution Approach 2:
Instead of removing tissue to relieve obstruction, the implant uses controlled mechanical compression of the enlarged prostate lobes to achieve the same therapeutic effect of improving urinary flow while preserving the integrity of surrounding functional tissues
Data Source
AI summary
Devices and systems are disclosed for managing and/or treating body tissues obstructing a hollow body lumen, including the prostatic lobe tissues obstructing the urethra, for example conditions including benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), benign prostatic obstruction (BPO) and associated lower urinary tract symptoms (LUTS). An implant is maintained in a constrained configuration within a distal portion of an elongated sheath so that is may be deployed by driving the implant with a pusher coaxially disposed within the sheath. An implant engaging element helps maintain control of the implant during deployment.